---
title: "BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286899389.md"
description: "BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News"
datetime: "2026-05-19T03:00:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286899389.md)
  - [en](https://longbridge.com/en/news/286899389.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286899389.md)
---

# BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News

### Related Stocks

- [BLRX.US](https://longbridge.com/en/quote/BLRX.US.md)

## Related News & Research

- [Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News](https://longbridge.com/en/news/286556016.md)
- [Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum](https://longbridge.com/en/news/286559312.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?](https://longbridge.com/en/news/286679819.md)
- [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md)